Moderna: CHMP gives green light to new Covid vaccine - MarketScreener
Moderna's updated COVID-19 mRNA vaccine, Spikevax, targeting the JN.1 variant, receives positive opinion from CHMP for authorization in EU for ages 6 months and over for autumn/winter 2024-2025 season, based on efficacy and safety data. Moderna has similar approvals in Japan, Taiwan, and the UK, and is participating in EU tender for Covid vaccines.
Reference News
Moderna's updated COVID-19 mRNA vaccine targeting SARS-CoV-2 variant JN.1 recommended by EMA's CHMP for EU authorization, pending EC decision for 2024-2025 season.
EMA's CHMP recommends marketing authorization for Moderna's updated COVID-19 mRNA vaccine targeting SARS-CoV-2 variant JN.1, for individuals 6 months and older, pending European Commission approval for the 2024-2025 vaccination season.
EMA's CHMP recommends Moderna's updated Covid-19 vaccine, Spikevax, targeting JN.1 variant for potential authorisation in 2024-2025. The recommendation is based on comprehensive data, following EMA's ETF guidance. The vaccine has been approved in Taiwan, Japan, and the UK, with ongoing reviews globally. Moderna participates in EU's mRNA vaccine procurement.
Moderna is close to securing EU approval for its updated COVID-19 vaccine, Spikevax, targeting the JN.1 variant. The EMA's CHMP recommended authorization, pending European Commission decision for the 2024-2025 season. Moderna's vaccine aims to enhance antibody responses against JN.1 and related lineages for individuals aged six months and older. The company has already secured approvals in Japan, Taiwan, and the UK, with ongoing reviews elsewhere. Moderna participates in the EU's HERA tendering process, potentially expanding vaccine reach. The company's mRNA platform supports rapid development of vaccines and therapeutics.
Moderna announced EMA's CHMP adopted a positive opinion recommending marketing authorization for an updated COVID-19 mRNA vaccine Spikevax targeting SARS-CoV-2 variant JN.1, for individuals six months and older. The European Commission will decide on its use for the 2024-2025 autumn/winter season.
Moderna's updated COVID-19 mRNA vaccine, Spikevax, targeting the JN.1 variant, receives positive opinion from CHMP for authorization in EU for ages 6 months and over for autumn/winter 2024-2025 season, based on efficacy and safety data. Moderna has similar approvals in Japan, Taiwan, and the UK, and is participating in EU tender for Covid vaccines.
Moderna's updated COVID-19 vaccine targeting the JN.1 strain of Omicron receives a positive opinion from the EMA's CHMP, paving the way for marketing authorization in the EU for the 2024-2025 respiratory season.
Moderna's updated COVID-19 mRNA vaccine, Spikevax, targeting SARS-CoV-2 variant JN.1, received a positive recommendation from the European Medicines Agency's CHMP. The vaccine is intended for individuals aged six months and above, expected for the 2024-2025 vaccination season. Moderna also participates in HERA's tendering procedure for mRNA COVID-19 vaccines.
Moderna's COVID-19 mRNA vaccine for SARS-CoV-2 variant JN.1 received a positive opinion from EMA's CHMP, recommended for the 2024-2025 EU vaccination season, pending final authorization. This vaccine is part of Moderna's strategy to adapt to evolving variants, with approvals already in Japan, Taiwan, the UK, and the US.